

REMARKS

Claims 1, 33, 36, and 50 remain in the present application. Claims 1, 33, and 36 have been allowed. Claim 50 is amended herein. Support for this claim can be found on page 57, lines 5-17.

Rejection Under 35 U.S.C. §102(b)

Claim 50 was rejected under 35 U.S.C. §102(b) as anticipated by EMBL Accession No. AAB39218. The Examiner argued:

This sequence is a mouse kinase that is 97.5% identical to instant SEQ ID NO. 66 (see attached alignment) and thus anticipates the limitations of Claim 50.

In response, Applicants amended claim 50 to recite: An isolated polypeptide comprising an amino acid sequence at least 98% identical to SEQ ID NO: 66, wherein said polypeptide has kinase activity.

In view of this amendment, Applicant submits that claim 50 is no longer anticipated by the above-referenced sequence. Accordingly, Applicant respectfully requests withdrawal of this ground of rejection.

Respectfully submitted,

George Yalwak, Reg. No. 26,824
CuraGen Corporation
555 Long Wharf Drive
New Haven, CT 06511
Tel: (203) 974-6303

Dated: March 2, 2005